Jonathan D Schertzer Selected Research

Glycemic Control

10/2023	Microbiota and Nod-like receptors balance inflammation and metabolism during obesity and diabetes.
1/2023	Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin.
1/2022	Postbiotics engage IRF4 in adipocytes to promote sex-dependent changes in blood glucose during obesity.
1/2022	Increased gut serotonin production in response to bisphenol A structural analogs may contribute to their obesogenic effects.
1/2020	RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice.
11/2018	Long term but not short term exposure to obesity related microbiota promotes host insulin resistance.
11/2018	Targeting macrophage scavenger receptor 1 promotes insulin resistance in obese male mice.
8/2017	The Gut Microbiota as a Mediator of Metabolic Benefits after Bariatric Surgery.
1/2016	Different Th17 immunity in gut, liver, and adipose tissues during obesity: the role of diet, genetics, and microbes.
12/2015	Immunometabolism of obesity and diabetes: microbiota link compartmentalized immunity in the gut to metabolic tissue inflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jonathan D Schertzer Research Topics

Disease

35	Inflammation (Inflammations) 05/2024 - 01/2009
33	Insulin Resistance 10/2023 - 01/2009
27	Obesity 05/2024 - 11/2010
10	Type 2 Diabetes Mellitus (MODY) 01/2023 - 12/2011
8	Metabolic Diseases (Metabolic Disease) 10/2022 - 12/2015
6	Neoplasms (Cancer) 01/2023 - 04/2005
5	Glucose Intolerance 01/2023 - 01/2013
5	Hypertrophy 01/2023 - 04/2006
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 04/2014
5	Muscular Dystrophies (Muscular Dystrophy) 04/2012 - 01/2007
4	Muscular Diseases (Myopathy) 01/2016 - 04/2006
3	Dysbiosis 01/2023 - 03/2015
3	Non-alcoholic Fatty Liver Disease 01/2022 - 12/2013
3	Endotoxemia 01/2022 - 05/2017
3	Hyperinsulinism (Hyperinsulinemia) 12/2020 - 01/2013
3	Heart Failure 01/2020 - 03/2007
3	Fatigue 04/2017 - 09/2006
3	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 04/2012 - 04/2005
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/2024 - 01/2023
2	Colitis 05/2023 - 12/2022
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 10/2018
2	Infections 01/2020 - 01/2016
2	Hyperglycemia 12/2018 - 10/2018
2	Sarcopenia 01/2017 - 08/2007
2	Cachexia 03/2007 - 04/2005
1	Dyslipidemias (Dyslipidemia) 01/2023
1	Fibrosis (Cirrhosis) 01/2023
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Colonic Neoplasms (Colon Cancer) 01/2022
1	Weight Gain 01/2022
1	Crohn Disease (Crohn's Disease) 01/2021

Drug/Important Bio-Agent (IBA)

22	Insulin (Novolin)FDA Link 01/2023 - 01/2009
17	Glucose (Dextrose)FDA LinkGeneric 05/2024 - 01/2009
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2010
11	Blood Glucose (Blood Sugar)IBA 05/2024 - 01/2017
9	LipidsIBA 01/2023 - 09/2011
9	NucleotidesIBA 01/2022 - 12/2010
8	InflammasomesIBA 01/2020 - 04/2014
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 11/2014
6	Peptidoglycan (Murein)IBA 01/2019 - 09/2011
5	LigandsIBA 10/2023 - 12/2010
5	Phosphotransferases (Kinase)IBA 01/2023 - 01/2009
5	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 10/2009
5	CytokinesIBA 12/2018 - 04/2005
4	LipopolysaccharidesIBA 10/2023 - 05/2017
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 05/2017
4	CholesterolIBA 01/2020 - 10/2015
4	Insulin-Like Growth Factor I (IGF-1)IBA 11/2008 - 04/2006
3	Acetylmuramyl-Alanyl-IsoglutamineIBA 10/2023 - 05/2017
3	Serotonin (5 Hydroxytryptamine)IBA 05/2023 - 02/2015
3	AMP-Activated Protein KinasesIBA 01/2020 - 12/2013
3	Fluvastatin FDA Link 01/2017 - 11/2014
3	Pattern Recognition ReceptorsIBA 03/2015 - 12/2010
3	Formoterol Fumarate (Oxis)FDA Link 07/2008 - 01/2007
2	NLR ProteinsIBA 10/2023 - 11/2014
2	Allura Red AC Dye (FD & C red no. 40)IBA 05/2023 - 12/2022
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2023 - 01/2021
2	EnzymesIBA 12/2022 - 09/2011
2	SugarsIBA 10/2022 - 01/2022
2	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 12/2013
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021 - 12/2010
2	Terpenes (Terpenoids)IBA 01/2020 - 01/2019
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2017
2	DiglyceridesIBA 01/2019 - 12/2011
2	Caspase 1 (ICE Protease)IBA 01/2019 - 11/2014
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2018 - 04/2017
2	ResveratrolIBA 10/2018 - 04/2017
2	Insulin Receptor Substrate ProteinsIBA 01/2013 - 12/2010
2	DystrophinIBA 04/2012 - 01/2008
2	p38 Mitogen-Activated Protein KinasesIBA 12/2010 - 01/2009
2	Anabolic AgentsIBA 01/2007 - 04/2005
1	Lactic Acid (Lactate)FDA LinkGeneric 05/2024
1	Immunoglobulins (Immunoglobulin)IBA 10/2023
1	Interleukin-18 (Interleukin 18)IBA 10/2023
1	Ethanolamine (Colamine)IBA 10/2023
1	Short-Acting InsulinIBA 10/2023
1	NitratesIBA 01/2023
1	Protein Kinases (Protein Kinase)IBA 01/2023
1	Tryptophan HydroxylaseIBA 12/2022
1	Myosin-Light-Chain KinaseIBA 12/2022
1	Dietary SugarsIBA 10/2022
1	PropionatesIBA 01/2022
1	Volatile Fatty AcidsIBA 01/2022
1	Carrier Proteins (Binding Protein)IBA 01/2022
1	SterolsIBA 01/2022
1	Interferon Regulatory FactorsIBA 01/2022
1	Butyrates (Butyrate)IBA 01/2022
1	IronIBA 05/2021
1	Dietary Fiber FDA Link 01/2021
1	AntioxidantsIBA 01/2021
1	EndotoxinsIBA 01/2021
1	Glucagon-Like Peptides (Enteroglucagon)IBA 01/2021
1	Inositol (Myoinositol)IBA 01/2021
1	Lipid AIBA 01/2021
1	Ribonucleases (Ribonuclease)IBA 01/2021
1	Sucrose (Saccharose)IBA 01/2021

Therapy/Procedure

10	Glycemic Control 10/2023 - 12/2015
6	Therapeutics 01/2017 - 11/2008
1	Transplantation 01/2023
1	Immunotherapy 01/2021